Roswell Park Cancer Institute ( Site 6009) — Buffalo, New York

Roswell Park Cancer Institute ( Site 6009) is a clinical research site located in Buffalo, New York, United States 14263.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Roswell Park Cancer Institute ( Site 6009) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Urinary Bladder Neoplasms.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Roswell Park Cancer Institute ( Site 6009)?

Roswell Park Cancer Institute ( Site 6009) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Roswell Park Cancer Institute ( Site 6009) conducted?

Roswell Park Cancer Institute ( Site 6009) has 1 clinical trials on record, with 1 currently active. Their work covers Urinary Bladder Neoplasms.

Is Roswell Park Cancer Institute ( Site 6009) accredited by Crixeo Health?

Roswell Park Cancer Institute ( Site 6009) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Roswell Park Cancer Institute ( Site 6009)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.